Rakovina Therapeutics Secures Exclusivity on kt-5000 Target Profile
Rakovina amended its Variational AI agreement to secure exclusivity on the defined kt-5000 ATR inhibitor target profile and receive additional optimization cycles through year-end at no extra cost. Higher milestone payments are due upon candidate nomination and out-licensing.